Beijing Winsunny Pharmaceutical CO.LTD (601089) — Cash Flow Reinvestment Rate

Latest as of December 2024: 0.58x

Beijing Winsunny Pharmaceutical CO.LTD (601089) has a Cash Flow Reinvestment Rate of 0.58x as of December 2024, reinvesting CN¥403.39 Million (capex CN¥391.52 Million plus investments CN¥11.87 Million) from operating cash flow of CN¥690.75 Million. Explore Beijing Winsunny Pharmaceutical CO.LTD capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.58x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥403.39 Million
Capex + Investments

Operating Cash Flow

CN¥690.75 Million
CNY

Capital Expenditures

CN¥391.52 Million
CNY

Beijing Winsunny Pharmaceutical CO.LTD Cash Flow Reinvestment Rate (2020–2024)

Historical reinvestment intensity for Beijing Winsunny Pharmaceutical CO.LTD across 5 annual periods. Also explore Beijing Winsunny Pharmaceutical CO.LTD (601089) total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)

Year-by-year capital reinvestment analysis for Beijing Winsunny Pharmaceutical CO.LTD. For live market cap and broader valuation context, see 601089 stock market capitalisation.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 0.58x CN¥403.39 Million CN¥690.75 Million CN¥391.52 Million ▼ -11.9%
2023 0.66x CN¥368.49 Million CN¥555.90 Million CN¥366.08 Million ▲ +162.2%
2022 0.25x CN¥166.81 Million CN¥659.76 Million CN¥135.40 Million ▼ -69.2%
2021 0.82x CN¥433.12 Million CN¥528.02 Million CN¥192.97 Million ▼ -21.1%
2020 1.04x CN¥401.81 Million CN¥386.65 Million CN¥168.96 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow